Overview

Efficacy of Gemcitabine With Pazopanib as Second Line Treatment in Patient With Metastatic or Relapsed Uterine

Status:
Completed
Trial end date:
2019-05-28
Target enrollment:
Participant gender:
Summary
The aim of this research is to study the activity of pazopanib in second line after anthracyclines in extra uterus and uterine LMS in association with gemcitabine.
Phase:
Phase 2
Details
Lead Sponsor:
UNICANCER
Treatments:
Gemcitabine